


5020



#3
09/914191 PCT
JC10 Rec'd PGT/PTO 26 NOV 2001
PATENT
1377-0170P

IN THE PATENT AND TRADEMARK OFFICE

Applicant: BRADY et al. Conf.: 9468
Appl. No.: 09/914,191 Group: Unassigned
Filed: August 24, 2001 Examiner: UNASSIGNED
For: IDENTIFICATION OF GENES HAVING A ROLE
IN THE PRESENTATION OF DIABETIC
NEPHROPATHY

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE
OR CONCURRENTLY WITH A RULE 53(d) CPA APPLICATION
OR WITH A RULE 1.114 RCE APPLICATION)

Assistant Commissioner for Patents
Washington, DC 20231

November 26, 2001

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

II. COPIES (check at least one box)

- a. ☒ Submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- b. ☐ Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

a. ☒ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached patents, publications, or other information in the English language do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☐ **ENGLISH LANGUAGE SEARCH REPORT**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

FEEs

IV. ☒ THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b):
(check one box)

- a. ☒ within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. (This section is not to be used with RCE's and CPA's).
- b. ☐ within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.
- c. ☐ concurrently with the filing of a Continued Prosecution Application under 37 C.F.R. § 1.53(d) or concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
- d. ☐ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required.
In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. ☐ THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

- a. ☐ No statement; therefore, a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).
or
- b. ☐ See the statement below. No fee is required.

VI. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby states that

- a. ☐ each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.
- c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VII. PAYMENT OF FEES (check one box)

- ☐ A check in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p) is enclosed for the above-identified fee.
- ☐ Please charge Deposit Account No. 02-2448 in the amount required by 37 C.F.R. § 1.17(p) for the above-indicated fee. A triplicate copy of this paper is attached.
- ☒ No fee is required.

Appl. No. 09/914,191

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Gerald M. Murphy, Jr. (610-400-065)
Gerald M. Murphy, Jr., #28,977

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

GMM/MAA/csp
1377-0170P


Enclosures: ☒ PTO-1449
☒ Documents
☐ Foreign Search Report
☐ Fee
☐ Other:

(Rev. 10/31/01)

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

ATTY DOCKET NO.
1377-0170PAPPLICATION NO.
09/914,191APPLICANT
BRADY et al.FILING DATE
August 24, 2001GROUP
Unassigned**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

	OZAKI et al., <i>Cancer Research</i> , Vol. 55 (1995) pp. 895-900.
	Topol et al., <i>Molecular and Cellular Biology</i> , Vol. 17, No. 8 (1997) pp. 4801-4810.
	Ghosh-Choudhury et al., <i>Biochemical and Biophysical Research Communications</i> , Vol. 258 (1999) pp. 490-496.
	Ghosh-Choudhury et al., <i>J. of Biological Chemistry</i> , Vol. 274, No. 16 (1999) pp. 10897-10902.
	Brenner et al., <i>New England Journal of Medicine</i> , Vol. 307, No. 11 (1982) pp. 652-659.
	Stewart et al., <i>Clin. Genet.</i> , Vol. 49 (1996) pp. 152-155.
	Guffanti et al., <i>TIG</i> , Vol. 14, No. 7 (1998) p. 293.
	Altschul et al., <i>Nucleic Acids Research</i> , Vol. 25, No. 17 (1997) pp. 3389-3402.
	ITO et al., <i>Kidney Int.</i> , Vol. 53 (1998) pp. 853-861.
	Bradham et al., <i>J. of Cell Biology</i> , Vol. 114, No. 6 (1991) pp. 1285-1294.
	Bork, <i>FEBS Letts.</i> , Vol. 327, No. 2 (1993) pp. 125-130.
	Kreisberg et al., <i>Kidney Int.</i> , Vol. 43 (1993) pp. 109-113.
	Sohn et al., <i>BioEssays</i> , Vol. 16, No. 7 (1994) pp. 465-472.
	Zhou et al., <i>Kidney Int.</i> , Vol. 51 (1997) pp. 1797-1808.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

 ATTY DOCKET NO.
1377-0170P

 APPLICATION NO.
09/914,191

 APPLICANT
BRADY et al.

 FILING DATE
August 24, 2001

 GROUP
Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

	Zhou et al., <i>Lab. Invest.</i> , Vol. 73, No. 3 (1995) pp. 372-383.
	Zatz et al., <i>Proc. Natl. Acad. Sci.</i> , Vol. 82 (1985) pp. 5963-5967.
	Denton et al., <i>Am. J. Physiol.</i> , Vol. 261 (1991) pp. F1071-F1079.
	Brady et al., <i>Kidney Int.</i> , Vol. 42 (1992) pp. 480-487.
	Zuniga et al., <i>Nature</i> , Vol. 401 (1999) pp. 598-602.
	Hsu et al., <i>Molecular Cell</i> , Vol. 1 (1998) pp. 673-683.
	Sharma et al., <i>Diabetes</i> , Vol. 45 (1996) pp. 522-530.
	Park et al., <i>Diabetes</i> , Vol. 46 (1997) pp. 473-480.
	Sharma et al., <i>Diabetes</i> , Vol. 44 (1995) pp. 1139-1146.
	Goldfarb et al., <i>Diabetes</i> , Vol. 40 (1991) pp. 465-471.
	Cohen et al., <i>Kidney Int.</i> , Vol. 45 (1994) pp. 475-484.
	Brownlee et al., <i>Annals of Internal Medicine</i> , Vol. 101, No. 4 (1984) pp. 527-537.
	Fumo et al., <i>Am. J. Physiol.</i> , Vol. 267 (1994) pp. F632-F638.
	Derubertis et al., <i>Diabetes</i> , Vol. 43 (1994) pp. 1-8.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

ATTY DOCKET NO.
1377-0170P

APPLICATION NO.
09/914,191

APPLICANT
BRADY et al.

FILING DATE
August 24, 2001

GROUP
Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
					YES NO

OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

Hubank et al., *Nucleic Acids Research*, Vol. 22, No. 25 (1994) pp. 5640-5648.

Liang et al., *Science*, Vol. 257 (1992) pp. 967-971.

Gurskaya et al., *Analytical Biochemistry*, Vol. 240 (1996) pp. 90-97.

Ayo et al., *Am. J. Physiol.*, Vol. 260 (1991) pp. F185-F191.

Wahab et al., *Biochem. J.*, Vol. 316 (1996) pp. 985-992.

Ayo et al., *Am. J. Pathol.*, Vol. 136, No. 6 (1990) pp. 1339-1348.

Yazaki et al., *Anticancer Research*, Vol. 18 (1998) pp. 2339-2344.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.